Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated May 15, 2020 (6 years ago)

Doxycycline Hyclate tablets USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed dissolution specifications

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Doxycycline Hyclate tablets USP, 100 mg, packaged in bottles a) 6-count (NDC 55289-866-06), b) 10-count (NDC 55289-866-10), c) 14-count (NDC 55289-866-14), d) 20-count (NDC 55289-866-20), e) 28-count (NDC 55289-866-28), f) 30-count (NDC 55289-866-30), g) 60-count (NDC 55289-866-60), h) 120-count (NDC 55289-866-98), i) 210-count (NDC 55289-866-71), j) 300-count (NDC 55289-866-87), k) 400-count (NDC 55289-866-74), Rx only, PD-Rx Pharmaceuticals Incorporated Oklahoma City, OK 73127

Affected NDCs 55289-0866-06 55289-0866-10 55289-0866-14 55289-0866-20 55289-0866-28 55289-0866-30 55289-0866-60 55289-0866-71 55289-0866-74 55289-0866-87 55289-0866-98

Compare with the code on your package — it is the most precise check available.

Drug: Doxycycline Category: Antibiotic

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Doxycycline
Doxycycline Hyclate
NDC 55289-0866
100 mg/1 Tablet, Coated
Oral
PD-Rx Pharmaceuticals, Inc. Rx
Recalling firm
PD-Rx Pharmaceuticals, Inc.
NDC code
55289-866-06
Origin
OK, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1276-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Doxycycline recalls

See all
Class II · Moderate risk

Doxycycline Hyclate Tablets

Failed dissolution specifications: Stability testing found that the lot did not meet dissolution specifications.

Ongoing Dissolution failure Acella Pharmaceuticals, LLC NDC 42192-501-05 D-0014-2026
Class II · Moderate risk

Doxycycline

Lack of Processing Controls: Insanitary conditions observed during recent FDA Inspection

Terminated cGMP deviation Wedgewood Village Pharmacy, LLC D-1182-2022
Class II · Moderate risk

Doxycycline Capsules

cGMP deviations: Temperature abuse

Terminated Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 63304-616-50 D-1032-2022
Class II · Moderate risk

Doxycycline Capsules

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Terminated Temperature excursion Cardinal Healthcare NDC 68180-652-08 D-0178-2024

Other recalls by PD-Rx Pharmaceuticals, Inc.

All 2020 recalls
Class II · Moderate risk

DULoxetine DR USP

CGMP Deviations: the presence of a Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Duloxetine above the interim acceptable intake limit

Terminated Nitrosamine impurity PD-Rx Pharmaceuticals, Inc. D-0163-2025
Class II · Moderate risk

Glimepiride USP

CGMP deviations.

Terminated cGMP deviation PD-Rx Pharmaceuticals, Inc. NDC 43063-0587-90 D-0559-2023